Qing Wen

机构：University of Electronic Science and Technology of China, Jinan Central Hospital, Shandong First Medical University · ORCID：0000-0002-6408-2370

发表论文 59 篇 · 总被引 980 次 · h-index 13

代表论文

• Low miR-224–5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4 (2025 · Drug Resistance Updates · 被引 17)
• Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. (2024 · Journal of Clinical Oncology · 被引 14)
• Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric/gastroesophageal junction cancer: Results from ongoing phase I/II study. (2025 · Journal of Clinical Oncology · 被引 7)
• Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial. (2023 · Journal of Clinical Oncology · 被引 7)
• Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study. (2025 · Journal of Clinical Oncology · 被引 6)
• Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients (2023 · Clinical Pharmacology in Drug Development · 被引 6)